Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Song

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Blood Cancer Journal|September 5, 2023
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group databaseJulie Côté, Richard LeBlanc, Hira Mian, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 28, 2025
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical DatabaseJulia Varghese, Christopher P Venner, Martha Louzada, et al.
Cancer Medicine|November 5, 2024
Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database StudyMégane Tanguay, Jean Roy, Jiandong Su, et al.
Leukemia|May 8, 2020
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatmentDavid S Siegel, Gary J Schiller, Christy Samaras, et al.
Blood|July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaDavid S Siegel, Thomas Martin, Michael Wang, et al.
Blood|January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyPaul G Richardson, David S Siegel, Ravi Vij, et al.
Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
The Lancet. Oncology|September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialJesus San Miguel, Katja Weisel, Philippe Moreau, et al.
European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Blood|January 9, 2013
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 TrialA Keith Stewart, Suzanne Trudel, Nizar J Bahlis, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Blood Cancer Journal|September 5, 2023
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group databaseJulie Côté, Richard LeBlanc, Hira Mian, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 28, 2025
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical DatabaseJulia Varghese, Christopher P Venner, Martha Louzada, et al.
Cancer Medicine|November 5, 2024
Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database StudyMégane Tanguay, Jean Roy, Jiandong Su, et al.
Leukemia|May 8, 2020
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatmentDavid S Siegel, Gary J Schiller, Christy Samaras, et al.
Blood|July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaDavid S Siegel, Thomas Martin, Michael Wang, et al.
Blood|January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyPaul G Richardson, David S Siegel, Ravi Vij, et al.
Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
The Lancet. Oncology|September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialJesus San Miguel, Katja Weisel, Philippe Moreau, et al.
European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Blood|January 9, 2013
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 TrialA Keith Stewart, Suzanne Trudel, Nizar J Bahlis, et al.
Pageof 10